DexCom, Inc. (NASDAQ:DXCM) Position Raised by Abbot Financial Management Inc.

Abbot Financial Management Inc. raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,449 shares of the medical device company’s stock after purchasing an additional 455 shares during the period. Abbot Financial Management Inc.’s holdings in DexCom were worth $845,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Team Hewins LLC lifted its position in shares of DexCom by 3.4% in the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after acquiring an additional 83 shares in the last quarter. Bleakley Financial Group LLC raised its stake in DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC lifted its holdings in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares in the last quarter. Gulf International Bank UK Ltd boosted its position in shares of DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after buying an additional 93 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of DexCom by 10.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. Barclays reduced their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Redburn Atlantic initiated coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Oppenheimer decreased their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Finally, Stifel Nicolaus boosted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,483 shares of company stock worth $201,708. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.8 %

NASDAQ:DXCM opened at $70.09 on Tuesday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company’s 50 day moving average is $81.54 and its 200-day moving average is $110.92. The firm has a market cap of $27.87 billion, a price-to-earnings ratio of 45.22, a P/E/G ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.34 EPS. Equities analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.